Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of ...

Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...

Bristol-Myers Squibb Co (NYSE:BMY) shares are trading higher Monday. The stock appears to be reacting positively after AbbVie ...

BMY has been having a good run for the past three months. The stock recently touched a 52-week high. We believe there is more ...

AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...

Related: Bristol Myers Squibb's stock jumps on schizophrenia-drug ... The drug, previously called KarXT, is an oral medication for the treatment of schizophrenia in adults. Cobenfy introduces ...

Karuna’s crown jewel, an experimental drug called KarXT, is the product of such new insights. The drug could surpass $6 billion in yearly sales if it is approved for the various uses.

Yet, AbbVie’s emraclidine has floundered where Karuna prospered. AbbVie’s phase 2 trials tested emraclidine as a once-daily, oral monotherapy in adults with schizophrenia experiencing an acute ...

Bristol-Myers Squibb entered the schizophrenia treatment market through last year's acquisition of biopharma firm Karuna Therapeutics, whose drug KarXT received approval from the Food and Drug ...